Director buying at Profound Medical (T:PRN)

Arun Menawat, a Senior Officer and Director, acquired 153,700 Common Shares on a direct ownership basis at prices ranging from $0.657 to $0.686 between December 3rd, 2018 and December 4th, 2018. This represents a $102,825 investment into the company's shares and an account share holdings change of 18.9%.

Profound Medical is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Profound Medical Corp., formerly Mira IV Acquisition Corp., is a capital pool company. The Company is a medical device company focused on prostate cancer care. Its product consists of common electronic components, capital equipment and disposables. The Company is developing and commercializing a minimally invasive procedure for patients with prostate cancer, the Transurethral Ultrasound Ablation-PRO (TULSA-PRO) system. Its technology combines magnetic resonance imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland delivered through the urethra. Its real-time, MRI guided ultrasound procedure (TULSA) ablates the whole prostate gland, from the inside out, in a single session. It has completed a Phase l International Clinical Trial. The Phase I trial has demonstrated that magnetic resonance (MR)-guided TULSA provides treatment planning, real-time thermal dosimetry and control of prostate ablation to within approximately 1.3 millimeters.